[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369482-105":59,"doc-detail-369482-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunohistochemical-expression-of-pd-l1-and-ctla-4-in-triple-negative-breast-cancer-and-their-prognostic-associations-research-article","Immunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations - Research Article","","Objective: Determine whether PD-L1 and CTLA-4 can predict patient survival in Triple Negative Breast Cancer (TNBC). Methods: Retrospective cohort analysis of 100 primary TNBC cases after surgical resection at Mansoura University Oncology Center; clinicopathological data and survival outcomes were collected and immunohistochemistry assessed PD-L1 and CTLA-4 expression. Results: PD-L1 expressed in 29% and linked to high tumor grade; no significant survival association. CTLA-4 expressed in 45% and associated with metastasis and advanced TNM stage; multivariate analysis found CTLA-4 as independent predictor for disease-free and overall survival. Conclusion: CTLA-4 may guide selection for immunotherapy and checkpoint blockade.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunohistochemical-expression-of-pd-l1-and-ctla-4-in-triple-negative-breast-cancer-and-their-prognostic-associations-research-article/369482/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunohistochemical-expression-of-pd-l1-and-ctla-4-in-triple-negative-breast-cancer-and-their-prognostic-associations-research-article/369482.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of this TNBC study?","Question",{"text":112,"@type":113},"To determine whether PD-L1 and CTLA-4 expression could predict patients’ survival in Triple Negative Breast Cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many TNBC cases were included, and how were the biomarkers measured?",{"text":117,"@type":113},"The study analyzed 100 primary TNBC cases, assessing PD-L1 and CTLA-4 using immunohistochemistry on formalin-fixed, paraffin-embedded tissue blocks.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarker showed an independent prognostic value in multivariate analysis?",{"text":121,"@type":113},"CTLA-4 expression was identified as an independent prognostic predictor for both disease-free survival and overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369482,1790291250,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  \nEditorial Process: Submission:09/28/2024 Acceptance:01/16/2025  \nImmunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations  \nNehal Moaz Mehrez1 *, Dina Abdallah Ibrahim1, Maha Esmail El-Zaafarany2, DinaA El-Tantawy1, Azza Abdel-Aziz1  \nAbstract  \nObjective: Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) are presently considered as prognostic markers and therapeutic targets in numerous human malignancies. The goal of this study was to determine whether PD-L1 and CTLA-4 might be used to predict patients’ survival in Triple Negative Breast Cancer (TNBC). Methods: This retrospective cohort study analyzed 100 primary TNBC cases that had surgical resection at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt. Clinicopathological data and survival outcomes were collected, and immunohistochemistry (IHC) was performed for PD-L1 and CTLA-4 expression. Result: In 29% ofTNBCs, PD-L1 was expressed. PD-L1 positivity was significantly associated with high tumor grade (P=0.007). PD-L1 did not, however, significantly associate with survival. CTLA-4 was expressed in 45% ofTNBCs. CTLA-4 expression was significantly associated with lymph node metastasis (P=0.009), distant metastasis (P=0.001) and advanced TNM stage (P=0.001) . In TNBC, multivariate analysis identified CTLA-4 expression as an independent prognostic predictor for both disease-free survival (P=0.002) and overall survival (P=0.003) . Conclusion: The selection of patients for immunotherapy and checkpoint-blockade treatment may be guided by CTLA-4, an independent prognostic factor for the overall survival and disease-free survival ofTNBC patients.  \nKeywords: PD-L1-CTLA-4-TNBC-Survival-Immunotherapy  \nAsian Pac J Cancer Prev, 26 (1), 319-326  \nIntroduction  \nBreast cancer is the most common malignancy in females and is the most often diagnosed cancer in the great majority of countries [1]. In 2020, an estimated 2.3 million female breast cancer cases were diagnosed worldwide, and around 685,000 females died because of the disease [2] .  \nAbout 15–20% of all cases of breast cancer are Triple Negative Breast Cancer (TNBC), which is characterized by the lack of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) expression by immunohistochemical (IHC) analysis [3] . Because of the absence of HER2 expression and targetable hormone receptors, TNBC is often accompanied by a poor prognosis and a restricted selection of treatment routes [4] . These features highlight the significance of studying the pathogenesis and available treatments for TNBC.  \nBreast cancer was not formerly considered to be immunogenic. Nonetheless, in comparison with other  \nsubtypes of breast cancer, TNBC is associated with greater immune cell activity and abundance, which suggests that immunotherapy more particularly, the use of immune checkpoint inhibitors (ICIs) treatment may be beneficial [5] .  \nImmune checkpoints, that are co-stimulators or coinhibitors, firmly regulate the activation of T-cells [6] . Immune checkpoints frequently implicated in cancer pathogenesis are Programmed Death Protein 1 (PD-1), Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) [7] .  \nThe reduction of cytotoxic T-cell activity and proliferation is the outcome of the interaction between PD-1 and PD-L1, which also encourages the differentiation of regulatory T-cells and contributes to immune cell dysfunction [8] . T-cell immunological responses are inhibited by CTLA-4, an immunosuppressive cytokine belonging to the immunoglobulin superfamily [9] . Tumor cells in cancer patients have the ability to evade immune surveillance, takeover certain immunological checkpoint  \n1Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 2Medical Oncology Unit, Internal Medicine Department,","cbCaiu2IeJRpGk2M","https://ap.wps.com/l/cbCaiu2IeJRpGk2M","pdf",884573,"English","# Abstract\n# Introduction\n# Materials and Methods","[{\"question\":\"What was the main objective of this TNBC study?\",\"answer\":\"To determine whether PD-L1 and CTLA-4 expression could predict patients’ survival in Triple Negative Breast Cancer.\"},{\"question\":\"How many TNBC cases were included, and how were the biomarkers measured?\",\"answer\":\"The study analyzed 100 primary TNBC cases, assessing PD-L1 and CTLA-4 using immunohistochemistry on formalin-fixed, paraffin-embedded tissue blocks.\"},{\"question\":\"Which biomarker showed an independent prognostic value in multivariate analysis?\",\"answer\":\"CTLA-4 expression was identified as an independent prognostic predictor for both disease-free survival and overall survival.\"}]","Immunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations - Research Article | PDF",1790182937,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6e7c7a17821fa8595540c1a532fca67.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab2401b2bf6a8134166af0c518234aef.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2308339eddf700448dc5a9bd46767c0.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebad4686a293361375e1239ab7341b44.webp",980,1385]